InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
68,902.40
(
0.54%
)
Post# of 251938
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119690
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 210756

Tuesday, 10/24/2017 1:38:52 PM

Tuesday, October 24, 2017 1:38:52 PM

Post# of 251938
GILD reports phase-2 GS-0976 data in NASH:

https://finance.yahoo.com/news/gilead-announces-phase-2-results-123600277.html

The data demonstrate that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis (TIMP-1) compared to placebo.

Patients in this trial had fibrosis stage F1-F3, according to either a biopsy or an MRE/MRI. The lower dose tested, 5mg, did not show efficacy.

GILD picked up GS-0976 in the 2016 acquisition of (private) Nimbus Therapeutics for $400M up-front (#msg-121656679). It is one of several NASH candidates owned by GILD.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up